Medical management of lower urinary tract symptoms in men: Current treatment and future approaches

Nature Clinical Practice Urology

Volumn 5, Issue 4, 2008, Pages 211-219

  Patel, Anand K ^a   Chapple, Christopher R ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ATENOLOL; CAFFEINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; DUTASTERIDE; ENALAPRIL; FINASTERIDE; FLOMAXTRA; NIFEDIPINE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PLANT EXTRACT; SILDENAFIL; STEROID 5ALPHA REDUCTASE INHIBITOR; TADALAFIL; TAMSULOSIN; TOLTERODINE; UNCLASSIFIED DRUG; VARDENAFIL;

ALCOHOL WITHDRAWAL; ASTHENIA; BLADDER DYSFUNCTION; BLADDER NECK STENOSIS; BREAST TENDERNESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; DIAGNOSTIC ACCURACY; DIET RESTRICTION; DIGITAL RECTAL EXAMINATION; DISEASE ASSOCIATION; DISEASE COURSE; DIZZINESS; DRUG DOSAGE FORM COMPARISON; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FLUID INTAKE; GYNECOMASTIA; HEADACHE; HUMAN; HYPERTENSION; IMPAIRED BLADDER EMPTYING; IRIS DISEASE; LIBIDO DISORDER; LOWER URINARY TRACT SYMPTOM; MALE; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MEDICAL RESEARCH; MICTURITION DISORDER; MONOTHERAPY; NOCTURIA; ORTHOSTATIC HYPOTENSION; OVERACTIVE BLADDER; PATIENT CARE; PATIENT COMPLIANCE; PHYTOTHERAPY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE DISEASE; PROSTATE HYPERTROPHY; PROSTATE SURGERY; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; SOMNOLENCE; SURGICAL TECHNIQUE; SYMPTOM; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; URINARY HESITANCY; URINARY URGENCY; URINE INCONTINENCE; URINE RETENTION; URODYNAMICS; UROFLOWMETRY;

ADRENERGIC ALPHA-ANTAGONISTS; CHOLINERGIC ANTAGONISTS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HUMANS; MALE; PHYTOTHERAPY; PROSTATIC HYPERPLASIA; RISK FACTORS; TESTOSTERONE 5-ALPHA-REDUCTASE; URINARY BLADDER NECK OBSTRUCTION; URINATION DISORDERS;

EID: 42049118814     PISSN: 17434270     EISSN: 17434289     Source Type: Journal    
DOI: 10.1038/ncpuro1060     Document Type: Review

References (57)

1. Wei JT et al. (2005) Urologic diseases in America project: Benign prostatic hyperplasia. J Urol 173: 1256-1261
2. Chute CG et al. (1993) The prevalence of prostatism: A population-based survey of urinary symptoms. J Urol 150: 85-89
3. Roehrborn CG et al. (2006) Enlarged prostate: A landmark national survey of its prevalence and impact on US men and their partners. Prostate Cancer Prostatic Dis 9: 30-34
4. Issa MM and Regan TS (2007) Medical therapy for benign prostatic hyperplasia - present and future impact. AM J Manag Care 13 (Suppl 1): S4-S9
5. Irwin DE et al. (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol 50: 1314-1315
6. Hashim H and Abrams P (2006) Is the bladder a reliable witness for predicting detrusor overactivity? J Urol 175: 191-194
7. Abrams P et al. (2002) The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21: 167-178
8. Berry SJ et al. (1984) The development of human benign prostatic hyperplasia with age. J Urol 132: 474-479
9. Lytton B et al. (1968) The incidence of benign prostatic obstruction. J Urol 99: 639-645
10. Jacobsen SJ et al. (1997) Natural history of prostatism: Risk factors for acute urinary retention. J Urol 158: 481-487
11. McConnell J et al. (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 338: 557-563
12. Ball AJ et al. (1981) The natural history of untreated "prostatism". Br J Urol 53: 613-616
13. European Association of Urology Guidelines (2007). Guidelines on benign prostatic hyperplasia [http://www.uroweb.org/fileadmin/user_upload/ Guidelines/11%20BPH.pdf] (accessed 4 February 2008)
14. Crawford ED et al. (2006) Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 175: 1422-1426
15. Madersbacher S et al. (2004) EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 46:547-554
16. Chapple CR (2004) Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: An overview for the practising clinician. BJU Int 94: 738-744
17. Chapple C et al. (2006) New medical developments in the management of LUTS in adult men (World Health Organisation Report - Committee 6). In Male Lower Urinary Tract Dysfunction, 143-194 (Eds McConnell J et al.) Jersey: Health Publications Ltd
18. Nordling J (2005) Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int 95: 1006-1012
19. Roehrborn CG (2001) Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: A randomized, placebo-controlled trial. Urology 58 953-959
20. Mobley DF et al. (1997) Effect of doxazosin on the symptoms of benign prostatic hyperplasia: Results from three double-blind placebo-controlled studies. Int J Clin Pract 51: 282-288
21. Chapple CR et al. (1996) Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol 29: 155-167
22. MacDonald R and Wilt TJ (2005) Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: A systematic review of efficacy and adverse effects. Urology 66 780-788
23. Wilt TJ et al. (2002) Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: A systematic review of efficacy and adverse effects. J Urol 167: 177-183
24. Barendrecht MM et al. (2005) Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: The cardiovascular system. BJU Int 95 (Suppl 4): 19-28
25. van Kerrebroeck P et al. (2002) Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: Open-label extension study. Eur Urol 41: 54-60
26. Chapple CR et al. (1997) Tamsulosin 0.4 mg once daily: tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). The European Tamsulosin Study Group. Eur Urol 32: 462-470
27. Lowe FC (1997) Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: Pharmacodynamic effect. Clin Ther 19: 730-742
28. Lowe FC (2005) Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Sexual function. BJU Int 95 (Suppl 4): 12-18
29. Kloner RA et al. (2004) Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 172: 1935-1940
30. Chang DF and Campbell JR (2005) Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg 31: 664-673
31. Chapple CR (2005) The Oral Controlled Absorption System (OCAS®): The evolution of tamsulosin for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). Eur Urol Suppl 4: 20-22
32. Speakman MJ et al. (2004) Guideline for the primary care management of male lower urinary tract symptoms. BJU Int 93: 985-990
33. Bruskewitz R et al. (1999) Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 54: 670-678
34. Andriole GL and Kirby R (2003) Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 44: 82-88
35. Edwards JE and Moore RA (2002) Finasteride in the treatment of clinical benign prostatic hyperplasia: A systematic review of randomised trials. BMC Urol 2: 14
36. Roehrborn CG et al. (2004) Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 63: 709-715
37. McConnell JD et al. (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349: 2387-2398
38. Barkin J et al. (2003) Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol 44: 461-466
39. Baldwin KC et al. (2001) Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology 58: 203-209
40. Kaplan SA and Gonzalez RR (2007) Phosphodiesterase type 5 inhibitors for the treatment of male lower urinary tract symptoms. Rev Urol 9 73-77
41. Uckert S et al. (2001) Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 166: 2484-2490
42. Adolfsson PI et al. (2002) Lysophosphatidic acid stimulates proliferation of cultured smooth muscle cells from human BPH tissue: sildenafil and papaverin generate inhibition. Prostate 51: 50-58
43. Mulhall JP et al. (2006) Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 3: 662-667
44. McVary KT et al. (2007) Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 177 1401-1407
45. McVary KT et al. (2007) Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: A randomized, double-blind trial. J Urol 177: 1071-1077
46. Kaplan SA et al. (2007) Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 51: 1717-1723
47. Crawford ED (2005) Management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: The central role of the patient risk profile. BJU Int 95 (Suppl 4): 1-5
48. GlaxoSmithKline (online 22 December 2004) Study Number: ARI40001 -Year 1. [http://ctr.gsk.co.uk/Summary/dutasteride/studylist.asp] (Accessed 13 January 2008)
49. Kaplan S et al. (2000) Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. The Pless Study Group. Urology 56: 610-616
50. de Nunzio C et al. (2003) The evolution of detrusor overactivity after watchful waiting, medical therapy and surgery in patients with bladder outlet obstruction. J Urol 169: 535-539
51. Abrams P et al. (2006) Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 175: 999-1004
52. Blake-James BT et al. (2007) The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis. BJU Int 99 85-96
53. Kaplan SA et al. (2005) Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 174: 2273-2275
54. Lee KS et al. (2005) Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: A prospective, randomized, controlled multicenter study. J Urol 174: 1334-1338
55. Kaplan SA et al. (2006) Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: A randomized controlled trial. JAMA 296: 2319-2328
56. Yang Y et al. (2007) Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: A prospective study. Chin Med J (Engl) 120: 370-374
57. Novara G et al. (2006) Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: A systematic review. Eur Urol 50: 675-683